Apeloa Pharmaceutical Co. Ltd. Class A
SSZSE:00073919.68
CNY
-1.20
(-5.75%)
Apeloa Pharmaceutical Co. Ltd. Class A
SZSE:000739
(Shenzhen Stock Exchange)
Recent
price
19.68
P/E
ratio
- -
div
yld
1.27%
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Apeloa Pharmaceutical Co., Ltd., founded in 1989 and headquartered in Zhejiang, China, is a leading international supplier of generic active pharmaceutical ingredients (APIs) and a provider of comprehensive pharmaceutical manufacturing solutions. The company specializes in manufacturing APIs through chemical synthesis and biosynthesis, with a diverse product portfolio covering major therapeutic areas including anti-infectives, cardiovascular, oncology, central nervous system, traditional Chinese medicine, blood and blood-forming organs, respiratory, alimentary tract and metabolism, and musculo-skeletal systems. Apeloa's core products include Cefixime series, Metoprolol Succinate Extended-Release Tablets, Bupropion HCL XL Tablets, Ubenimex Capsules, Flucloxacillin Sodium for Injection, Levetiracetam Tablets, Amantadine Hydrochloride Tablets, Levofloxacin Tablets, and Scutellariae granules. The company also provides finished dosage forms such as immediate-release, enteric-coated, extended-release tablets, minitabs, bilayer tablets, dispersible tablets, dry suspensions, granules, solutions, small aqueous injections, and lyophilized powder injections. Its service offerings include active pharmaceutical ingredients (API), contract development and manufacturing organization (CDMO) services, finished dosage form (FDF) manufacturing, and aesthetic and care ingredients, supported by seven API manufacturing sites and two drug product sites globally. Recent strategic developments include the grand opening of the Apeloa Pharma Solutions R&D Center in Billerica, Massachusetts, in 2024, enhancing its research capabilities. The company appointed leading scientists to its advisory board and launched new API products such as Gabapentin. It successfully passed its 20th U.S. FDA inspection with a No Action Indicated (NAI) status at its subsidiary Zhejiang Apeloa Tospo Pharmaceutical Co., Ltd., reflecting strong regulatory compliance. Apeloa expanded its portfolio with FDA approvals for Amantadine Hydrochloride Tablets and Metoprolol Succinate Extended-Release Tablets in 2024. In 2025, the company’s subsidiary received China regulatory approval for antibiotics including Cefdinir Capsules and obtained registration for Levocarnitine Injection. Apeloa also announced a significant equity buyback plan worth CNY 360 million to enhance shareholder value. A strategic tie-up with Anticon Biotech was established to strengthen its CDMO business segment, focusing on advanced technology and integrated pharmaceutical solutions. Apeloa operates within the pharmaceutical industry segments of generic APIs, CDMO, finished dosage forms, and aesthetic care ingredients, serving both domestic Chinese and international pharmaceutical markets. It maintains strategic partnerships with top global pharmaceutical companies and adheres to high regulatory standards enforced by agencies including the National Medical Products Administration (NMPA) of China, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMEA), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). The company employs a technology-driven and compliance-focused business model with annual R&D investment exceeding 5% of revenue, aiming to deliver high-quality, affordable medicines and integrate innovative pharmaceutical manufacturing capabilities worldwide. Apeloa is a publicly traded company listed on the Shenzhen Stock Exchange under ticker 000739.SZ and is affiliated with the Hengdian Group.